Opioid Use Disorder Market - Trend, Growth, Forecast 2024–2032

Opioid Use Disorder Market Synopsis:

Opioid Use Disorder Market Size Was Valued at USD 3.0 Billion in 2023, and is Projected to Reach USD 7.37 Billion by 2032, Growing at a CAGR of 10.5% From 2024-2032.

Opioid use disorder market therefore captures the industry about drugs, treatments, therapies, and products intended for the management of opioid dependence. This is a chronic and relapsing brain disease characterized by uncontrollable drug seeking behavior and use of the drug, opioids, despite adverse consequences This is due mainly due to the increased prescriptions opioids, heroin and synthetic opioids such as fentanyl. The market is vast and extends across a vast network beginning with pharmaceutical firms that produce substances like buprenorphine and naltrexone and extending to healthcare facilities that offer treatment programs and government and non-government organizations that fund the creation of awareness and rehabilitation programs. This one has a central task of dealing with the increasing social and financial costs of OUD.

The market for opioid use disorder has been on the rise in the recent past years due to the raising rates of the condition across the world and improved efforts to tackle opioid crisis. governments and organizations across the world are raising the bar in the fight against the crisis with increased healthcare insurance to cater for addiction treatment, increased advocacy for medication-assisted therapies or what is commonly known as MAT. Furthermore, there are new product developments featuring enhanced conformities and purpose built delivery systems which have significantly enhanced the compliance and efficacy of treatments.

The market is comprised of large pharmaceutical firms and new biotechnology companies both competing to serve this niche. Currently, there are more FDA approved medications for OUD and there are campaigns and general calls to diagnose and treat it early which makes the situation much more promising. The usage of technology for patient care and the use of telemedicine has advanced the management of patient care and ensured that they receive proper care due to the addition of technology to health care provision this has prevailed even in remote areas.

Opioid Use Disorder Market Trend Analysis:

Rise of Telehealth in OUD Treatment

• Telehealth has turned into something of an innovation within the context of the opioid use disorder market because it is capable of providing an overall geographically distant link between the healthcare provider and the patient. The COVID-19 crisis also led to an earlier enhancement of telehealth (also known as telemedicine) which offered patients remote consultations and therapies, prescription renewals without face-to-face appointments. This approach has been particularly useful to the rural persons and those who cannot travel long distances. Additionally, details within the platforms include features for patient health monitoring, as well as for focusing on patient education with regard to compliance to the prescribed treatment for improved efficiency. Such a trend is likely to continually transform the market concerning convenience, the reduction of stigma, as well as overall access to care.

Expanding Access in Emerging Markets

• The opioid use disorder market can benefit from opportunities in emerging markets. Modernization and economic growth in Asia-Pacific, the Middle East, and Latin American nations are increasingly leading to a realization of the societal incidence of opioid dependence, and resulting healthcare development, rhetoric, and intervention. Unserved and under-served markets headlined by these regions offer an amazing opportunity for pharmacology companies as well as healthcare delivery systems. Furthermore, the increasing availability of generic drugs in these markets alongside a favorable government policy as well as funds from the international markets is expected to fuel the growth of the markets.

Opioid Use Disorder Market Segment Analysis:

Opioid Use Disorder Market is Segmented on the basis of Drug Type, Route of Administration, Distribution Channel, and Region

By Drug Type, Romiplostim segment is expected to dominate the market during the forecast period

• A Thrombopoietin Receptor agonist called Romiplostim is emerging as a new type of drug in the opioid use disorder market. Although traditionally it has been used for immune thrombocytopenia, current research indicates its possible applicability in managing some special concerns that relate to OUD like opioid-induced platelet dysfunction. The increased use of this product in various industries has led to high research and development activity in the pharmaceutical sector to incorporate it in its various forms and hence the segment on innovation is a crucial one.
• This market is dominated by romiplostim due to its strong clinical performance and expanded use in effective OUD treatment protocols. The effectiveness of the drug to alleviate severe health complication and improve the quality of patients’ outcomes is a factor that makes it a drug of choice by health practitioners a factor likely to fuel market share during the forecast period.

By Route of Administration, Oral segment expected to held the largest share

• Oral route of administration is again the most commonly used in opioid use disorder treatment due to the reason that they are easily available, patient compliance and they are easily accessible in forms like tablets, capsule etc. Oral administration of medications including buprenorphine and methadone provide the basis of MAT due to the features like sustained release and duration of therapeutic effect.
• This dominance may also be associated with an increased innovation in drug delivery systems, specifically that the oral segment cannot be as easily abused as some other forms due to these products’ recent adoption of controlled release technologies. Moreover, the compatibility of these drugs administrated orally make patients and caregivers to embrace them as well as the affordable healthcare costs making them maintain their dominance in the market.

Opioid Use Disorder Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

North America was identified as the most prominent in the market for OUD in 2023 because of the high incidences of OUD, well-developed healthcare systems, and increasing government support. of the global market, which is on account of its firm commitment to fighting the opioid epidemic through up of the MAT programs, policies, and research and development investments. Especially the United States still plays an important role, many drug manufacturers are based there and are currently working on creating new therapies.

Active Key Players in the Opioid Use Disorder Market:

• Alkermes (Ireland)
• Apotex Inc. (Canada)
• BioDelivery Sciences International (USA)
• Camurus AB (Sweden)
• Cipla Limited (India)
• Daiichi Sankyo Co., Ltd. (Japan)
• Dr. Reddy’s Laboratories (India)
• Indivior PLC (UK)
• Johnson & Johnson (USA)
• Lupin Limited (India)
• Mallinckrodt Pharmaceuticals (Ireland)
• Mylan N.V. (USA)
• Pfizer Inc. (USA)
• Purdue Pharma (USA)
• Sun Pharmaceutical Industries Ltd. (India)
• Other Active Players

Key Industry Development in the Opioid Use Disorder Market:

• In June 2024, Orchid Pharma Limited based in Chennai, India, the only Indian pharmaceutical company to have ever invented a New Chemical Entity announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a landmark collaboration, Orchid Pharma has partnered with Cipla Limited (‘Cipla’) to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.
• In December 2023, Alkermes plc announced today that it has completed an agreement to sell its development and manufacturing facility situated in Athlone, Ireland to Novo Nordisk, a leading international healthcare company. As per the agreement, after the transaction is finalized, Alkermes will obtain a one-time cash payment of $92.5 million for the facility and related assets, pending standard adjustments as outlined in the agreement.